CROI 2024 - CROI 2024

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1" by Russ P. Carstens Merck & Co., Inc.

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI" by Carl J. Fichtenbaum University of Cincinnati, Cincinnati, OH, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"VH3810109 (N6LS) in Adults With HIV-1 Who Are ART-Naive-: Phase IIa BANNER Efficacy Data" by Jan Losos ViiV Healthcare, Research Triangle Park, NC, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236" by Athe Tsibris Brigham and Women's Hospital, Boston, MA, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial" by Babafemi Taiwo Northwestern University, Chicago, IL, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab" by Joseph J. Eron University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Therapeutic Efficacy of a Triple Combination of HIV-1 Broadly Neutralizing Antibodies" by Boris D. Juelg Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results" by Nicholas Paton London School of Hygiene & Tropical Medicine, London, UK

Oral Abstract: Clinical Trials of Novel Antiretroviral Therapies

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Phase I Safety, Tolerability and Pharmacokinetics of Tenofovir Alafenamide Implants in African Women" by Tanuja N. Gengiah Centre for the AIDS Programme of Research in South Africa, Durban, South Africa

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Final Results of ANRS 174 DOXYVAC: A Randomized Trial to Prevent STI in MSM on PrEP" by Jean-Michel G. Molina University of Paris-Est, Paris, France

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Sustained Reduction of Bacterial STIs During the DoxyPEP Study Open-Label Extension" by Annie Luetkemeyer University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Doxycycline PEP: High Uptake and Significant Decline in STIs After Clinical Implementation" by Hyman M. Scott San Francisco Department of Public Health, San Francisco, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco" by Madeline Sankaran San Francisco Department of Public Health, San Francisco, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Site-Based HIV Testing Assay Performance for Cabotegravir and TDF-FTC PrEP Failure in HPTN 083" by Raphael J. Landovitz University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV" by Gillian Gillespie Merck & Co., Inc.,

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval" by Kelong Han GSK

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: HPTN 083" by Meredith Clement Louisiana State University, New Orleans, LA, USA

Oral Abstract: Game Changers in Prevention of HIV and Sexually Transmitted Infections

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: HIV Immunology and Vaccines

"INTRODUCTIONS (Part 1)" by

Oral Abstract: HIV Immunology and Vaccines

"Safety Profile and Immunogenicity of a Phase I Clinical Trial Using Germline-Targeting Trimer GT1.1" by Karlijn van der Straten Academic Medical Center, Amsterdam, Netherlands

Oral Abstract: HIV Immunology and Vaccines

"Vaccine Combining Slow-Delivery and Follicle-Targeting Improve Humoral and Germinal Center Responses" by Y. Jason Zhang Massachusetts Institute of Technology, Cambridge, MA, USA

Oral Abstract: HIV Immunology and Vaccines

"Multi-Specificity Is a Common Trait of HIV-1 Broad Neutralizing Capacity" by Alexandra Trkola University of Zurich, Zurich, Switzerland

Oral Abstract: HIV Immunology and Vaccines

"CD4 Binding Site Glycan-Deficient SHIVs Elicit Broadly Neutralizing Antibodies in Rhesus Macaques" by Daniel J. Morris University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: HIV Immunology and Vaccines

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: HIV Immunology and Vaccines

"INTRODUCTIONS (Part 2)" by

Oral Abstract: HIV Immunology and Vaccines

"MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques" by Philippe Rascle Duke University, Durham, NC, USA

Oral Abstract: HIV Immunology and Vaccines

"[18F]F-AraG PET Imaging Reveals Unique Tissue T-Cell Activation Patterns Across HIV Infection States" by Timothy J. Henrich University of California San Francisco, San Francisco, CA, USA

Oral Abstract: HIV Immunology and Vaccines

"Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI" by Preethi Krishnan AbbVie, Inc, North Chicago, IL, USA

Oral Abstract: HIV Immunology and Vaccines

"Live Single-Cycle SARS-CoV-2 Vaccine Elicits High Protection and Sterilizing Immunity" by Fabian Otte University of Basel, Basel, Switzerland

Oral Abstract: HIV Immunology and Vaccines

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Neuropathogenesis of HIV

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Neuropathogenesis of HIV

"Assessing the Contribution of Glial Activation to Cognitive Control and Declarative Memory in PWH" by Leah H. Rubin The Johns Hopkins University, Baltimore, MD, USA

Oral Abstract: Neuropathogenesis of HIV

"Associations Between Depressive Symptom Severity and Incident Stroke Among People With HIV" by Jimmy Ma University of Washington, Seattle, WA, USA

Oral Abstract: Neuropathogenesis of HIV

"Carotid Inflammation on FDG-PET Is Associated With Lower Cognitive Function in Treated HIV Infection" by Meg Wilson University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Neuropathogenesis of HIV

"Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation" by Laura P. Kincer University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: Neuropathogenesis of HIV

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Neuropathogenesis of HIV

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Neuropathogenesis of HIV

"HIV Transcription Persists in the Brain of People With HIV and Viral Suppression" by Melissa J. Churchill RMIT University, Melbourne, Australia

Oral Abstract: Neuropathogenesis of HIV

"Infected T-Cell Clones Are Shared Across CSF and Blood Compartments in PWH" by Shelli Farhadian Yale University, New Haven, CT, USA

Oral Abstract: Neuropathogenesis of HIV

"Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies" by Sharon R. Lewin University of Melbourne, Melbourne, Australia

Oral Abstract: Neuropathogenesis of HIV

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"INTRODUCTIONS (Part 1)" by

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"COVID Incidence and Severity in Persons With Reinfection vs Post-Vaccination Breakthrough Infection" by Adeel A. Butt Weill Cornell Medicine, New York, NY, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"MRNA Vaccine Versus Hybrid Immunity Against COVID-19 Among People With HIV During Omicron Wave" by Asa Tapley Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency" by Yijia Li University of Pittsburgh, Pittsburgh, PA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Analysis of Emergent SARS-CoV-2 Antiviral Resistance and Its Association With Virologic Rebound" by Trevor J. Tamura Brigham and Women's Hospital, Boston, MA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Molnupiravir Does Not Increase 3CLpro Resistance Mutations When Co-Administered With Nirmatrelvir/r" by Shuntai Zhou University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Mini-Lecture: Progress in Understanding the Mechanisms of Long COVID" by Annukka A. R. Antar The Johns Hopkins University, Baltimore, MD, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"Multimodal Assessment of Antigen Persistence in the Post-Acute Phase of SARS-CoV-2 Infection" by Michael J. Peluso University of California San Francisco, San Francisco, CA, USA

Oral Abstract: COVID-19: Epidemiologic and Clinical Insights

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Combating Complications of HIV

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Combating Complications of HIV

"Treatment of Prehypertension in People Living With HIV: A Randomized Controlled Trial" by Lily D. Yan Weill Cornell Medicine, New York, NY, USA

Oral Abstract: Combating Complications of HIV

"A Nurse-Led Strategy Improves Blood Pressure and Cholesterol in People With HIV: The EXTRA-CVD Trial" by Chris T. Longenecker University of Washington, Seattle, WA, USA

Oral Abstract: Combating Complications of HIV

"Community Health Worker-Facilitated Telehealth for Severe Hypertension Care in Kenya and Uganda" by Matt Hickey University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Combating Complications of HIV

"Pitavastatin Reduces Non-Calcified Plaque via Pro-Collagen PCOLCE Independently of LDL in REPRIEVE" by Márton Kolossváry Massachusetts General Hospital

Oral Abstract: Combating Complications of HIV

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Combating Complications of HIV

"Pitavastatin Has No Effect on Long-Term, Objective Physical Function in REPRIEVE" by Kristine M. Erlandson University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Oral Abstract: Combating Complications of HIV

"Lung Function, HIV and Mortality: Analyses From the AIDS Linked to the Intravenous Experience Cohort" by Sarath Raju The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Oral Abstract: Combating Complications of HIV

"Prostate Cancer Characteristics and Outcomes for Veterans With HIV in the Antiretroviral Era" by Keith Sigel Icahn School of Medicine at Mt Sinai, New York, NY, USA

Oral Abstract: Combating Complications of HIV

"InSTI Switch During Menopause Is Associated With Accelerated Body Composition Change" by Rebecca Abelman University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Combating Complications of HIV

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Hepatitis and Tuberculosis

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Hepatitis and Tuberculosis

"Simultaneous Initiation in ART-Naive PWH of DTG-Based ART & 3HP Maintains Efficacious DTG Levels" by Ethel D. Weld The Johns Hopkins University, Baltimore, MD, USA

Oral Abstract: Hepatitis and Tuberculosis

"Early Bactericidal Activity of the Alpibectir-Ethionamide (AlpE) Combination Against Tuberculosis" by Jeantelle Du Preez TASK Applied Science, Cape Town, South Africa

Oral Abstract: Hepatitis and Tuberculosis

"NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology" by Jennifer C. Price University of California San Francisco, San Francisco, CA, USA

Oral Abstract: Hepatitis and Tuberculosis

"Semaglutide Reduces Metabolic-Associated Steatotic Liver Disease in People With HIV: The SLIM LIVER" by Jordan E. Lake University of Texas at Houston, Houston, TX, USA

Oral Abstract: Hepatitis and Tuberculosis

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Hepatitis and Tuberculosis

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Hepatitis and Tuberculosis

"Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore" by Eshan U. Patel The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Hepatitis and Tuberculosis

"Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation" by Usman Arshad University of Liverpool, Liverpool, UK

Oral Abstract: Hepatitis and Tuberculosis

"Intrahepatic HDV Activity Is Fueled by Integrated HBV DNA-Derived HBs Independently From cccDNA Size" by Stefano D'Anna University of Rome Tor Vergata, Rome, Italy

Oral Abstract: Hepatitis and Tuberculosis

"A 4-Month Regimen of Quabodepistat, Delamanid, and Bedaquiline for Pulmonary TB: Interim Results" by Simbarashe Takuva Otsuka Novel Products GmbH

Oral Abstract: Hepatitis and Tuberculosis

"Provisional Results From a 3-month Clofazimine/Rifapentine-Containing Regimen for Drug-Sensitive TB" by John Metcalfe University of California, San Francisco

Oral Abstract: Hepatitis and Tuberculosis

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012-2021" by Patrick S. Sullivan Emory University, Atlanta, GA, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"HIV Incidence in Users of HIV Preexposure Prophylaxis in Australia: A Whole-of-Population Analysis" by Nicholas A. Medland University of New South Wales, Sydney, Australia

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"High PrEP Uptake and Adherence Measured Objectively Among Young African Women in the INSIGHT Cohort" by Brenda G. Mirembe Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Safety of Dapivirine Vaginal Ring and Oral PrEP for HIV Prevention in the Second Trimester" by Felix Mhlanga University of Zimbabwe College of Health Sciences Clinical Trials Research Centre

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Phone Calls for PrEP Persistence in Kenyan Women in Postabortal Care: A Cluster Randomized Trial" by Renee Heffron University of Alabama at Birmingham, Birmingham, AL, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Adherence Benchmarks for TFV-DP in DBS and PBMCs for African Women Using FTC/TDF PrEP" by Kenneth K. Mugwanya University of Washington, Seattle, WA, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"HIV Incidence in the INSIGHT Cohort of African Women: Recency Testing and Prospective Follow-Up" by Irene Mukui University of Washington, Seattle, WA, USA

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"Randomized Trial of SEARCH Dynamic Choice HIV Prevention Including Injectable Cabotegravir (CAB-LA)" by Moses R. Kamya Makerere University, Kampala, Uganda

Oral Abstract: Leaning Into the Success of Biomedical HIV Prevention

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"HIV-1 Transcription Start Sites Usage and Its Impact on Unspliced RNA Functions In Vivo" by Saiful Islam National Institutes of Health, Frederick, MD, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Investigation of the Functional Role of DDX42 in HIV-1 Viral RNA Splicing" by Xiao Lei The Rockefeller University, New York, NY, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Structural Basis of Translation Inhibition by MERS-CoV Nsp1 Reveals a Conserved Mechanism for β-CoVs" by Michael Vetick Yale University, New Haven, CT, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"“Traitor”-Virus-Guided Discovery of Novel Antiviral Factors" by Caterina Prelli Bozzo Ulm University Medical Center, Ulm, Germany

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Immunoregulatory Pathways Predict Mortality More Strongly in People With Versus Without HIV" by Samuel R. Schnittman Massachusetts General Hospital, Boston, MA, USA

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"HIV-1 Soluble gp120 Is Associated With Immune Dysfunction in Individuals on Antiretroviral Therapy" by Mehdi Benlarbi Université de Montréal, Montreal, Canada

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Rapid Emergence and Adaptive Evolution of SARS-CoV-2 Variants in Advanced HIV Infection" by Sung Hee Ko National Institutes of Health

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"Temperature-Dependent SARS-CoV-2 Spike-ACE2 Interaction Is Associated With Viral Transmission" by Andrés Finzi Université de Montréal, Montreal, Canada

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"IFNα2 Autoantibodies Post-SARS-CoV-2 Wave 1 in India Are Associated With Lower Omicron Symptomology" by Enrico Bravo King's College London, London, United Kingdom

Oral Abstract: Virus at the Wheel: Regulation of Replication and Immunity

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"INTRODUCTIONS (Part 1)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"High Rates of Viral Suppression in Pregnancy Drop Postpartum in South African Women on TLD" by Elaine J. Abrams Columbia University, New York, NY, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Hypertension in a Randomized Trial of DTG vs EFV-Based ART in Pregnant and Postpartum Women" by Risa Hoffman University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"ART-Free HIV-1 Remission in Very Early Treated Children: Results From IMPAACT P1115" by Deborah Persaud The Johns Hopkins University School of Medicine

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"GIVE MOVE: Randomized Trial on Genotype-Informed Management of Viremia in Children and Adolescents" by Jennifer A. Brown University Hospital Basel, Basel, Switzerland

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"INTRODUCTIONS (Part 2)" by

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"ODYSSEY 192-Week Follow-Up Evidences Superior Efficacy of DTG for Children on First/Second-Line ART" by Hilda A. Mujuru University of Zimbabwe

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Emerging Dolutegravir Resistance Among Children Being Investigated for Treatment Failure in Malawi" by George Bello International Training and Education Center for Health

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Long-Acting Cabotegravir Plus Rilpivirine In Adolescents With HIV: Week 24 IMPAACT 2017(MOCHA) Study" by Aditya Gaur St Jude Children's Research Hospital, Memphis, TN, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"SEARCH: Youth Intervention Impact on Symptoms of Depression in East African Youth Living With HIV" by James Ayieko Kenya Medical Research Institute, Nairobi, Kenya

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"Role of Community-Level Factors in Declines in HIV Incidence and Prevalence Among Rakai Adolescents" by John S. Santelli Columbia University Medical Center, New York, NY, USA

Oral Abstract: HIV Across the Life Continuum: Pregnant People, Infants, Children, and Adolescents

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: HIV Reservoir and Cure Strategies

"INTRODUCTIONS (Part 1)" by

Oral Abstract: HIV Reservoir and Cure Strategies

"Selection of Epigenetically Privileged HIV-1 Proviruses During Treatment With Panobinostat and IFNα" by Marie Armani-Tourret Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Role of Cytoskeleton and Adhesion in a Rare Subset of HIV-Infected Cells That Resist CTL" by Louise Leyre Weill Cornell Medicine, New York, NY, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Sex-Specific Innate Immune Selection in Vertical HIV Transmission and cART-Free Aviraemia in Males" by Gabriela Z.L. Cromhout University of KwaZulu-Natal

Oral Abstract: HIV Reservoir and Cure Strategies

"Sex-Based Differences in HIV-1 Reservoir Profile in Individuals With Long-Term ART Suppression" by Toong Seng Tan Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: HIV Reservoir and Cure Strategies

"AAV-Expressed HIV IgG Biologics Enable Durable ART-Free Viral Control in Infant Macaques" by Mauricio A. Martins University of Florida, Gainesville, FL, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Broadly Neutralizing Antibody-Secreting T Cells and CAR-Ts Potently Suppress In Vivo HIV Infection" by Hang Su Albert Einstein College of Medicine, Bronx, NY, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"Autologous Neutralizing Antibodies Contribute to Virus Control in a Subset of PWH Treated With bNAbs" by Katharine J. Bar University of Pennsylvania, Philadelphia, PA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"A T Cell-Targeting mRNA SIV Vaccine Extends Time to Rebound and Enhances Post-ART Viral Control" by Benjamin Varco-Merth Oregon Health and Sciences University, Portland, OR, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"IL-15/IL-15RA Cytokine Therapy Enhances Control of Viral Rebound in SIV-Infected Macaques" by Vijayakumar Velu Emory University, Atlanta, GA, USA

Oral Abstract: HIV Reservoir and Cure Strategies

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Together Take Me Home: Launch of a National HIV Self-Test Distribution Program, March-December 2023" by Kevin P. Delaney Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Incidence of Health Facility Switching and HIV Viral Rebound in Uganda: A Population-Based Study" by Joseph G. Rosen The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Improving Posthospital Outcomes in People With HIV: A Multicenter Randomized Trial in Tanzania" by Serena Koenig Harvard Medical School, Boston, MA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Lakeside Combined HIV and Schistosomiasis Services in Malawian Fishermen: A Cluster Randomized Trial" by Augustine T. Choko Liverpool School of Tropical Medicine, Liverpool, UK

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"What Are the Outcomes for Established Clients Enrolled in DSD During the First 3 Years on ART?" by Amy N. Huber University of the Witwatersrand, Johannesburg, South Africa

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Opt-Out HIV Testing in Emergency Departments Successfully Addresses Key Gaps in Testing" by Lisa Hamzah St George's University Hospitals NHS Foundation Trust

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Few Discordant HIV Ag/Ab and RNA Test Results Among Persons in a National Cohort of PrEP Users" by Weiming Zhu Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"Missed Opportunities to Prevent Congenital Syphilis in Antenatal PrEP Services in South Africa" by Dvora L. Joseph Davey University of California Los Angeles, Los Angeles, CA, USA

Oral Abstract: Strengthening Testing, Treatment, and Prevention of HIV and STIs

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"INTRODUCTIONS (Part 1)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Investigation of HIV Transmission Associated With Receipt of Vampire Facials: New Mexico, 2018-2023" by Anna M. Behar Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Trends in Black-White Disparities in HIV Diagnosis: 2017-2021, United States" by André Dailey Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Estimating Lifetime Risk of a Diagnosis of HIV Infection Among MSM: United States, 2017-2021" by Sonia Singh Centers for Disease Control and Prevention, Atlanta, GA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Quantifying HIV-1 Transmission Between People Who Inject Drugs and Other Populations in Kenya" by Hanley Kingston University of Washington, Seattle, WA, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"QUESTIONS AND ANSWERS (Part 1)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"INTRODUCTIONS (Part 2)" by

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Demographics Are Crucial to Interpret 95-95-95 Targets in African Populations With High ART Coverage" by Andrea Brizzi Imperial College London, London, UK

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"High Prevalence of Advanced HIV Disease in Sub-Saharan Africa: An Analysis of 11 Household Surveys" by Dominik Stelzle World Health Organization, Geneva, Switzerland

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Low-Level Viremia Trends Among Persons With HIV: A 5-Country Analysis From 10 PHIA Surveys" by Jessica E. Justman Columbia University Medical Center, New York, NY, USA

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"A New 2023-2024 Mpox Outbreak in Brazil: Lessons From a Reemerging Neglected Disease" by Mayara Secco Torres da Silva Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"Vaccine Effectiveness Against COVID In-Hospital Mortality by HIV Status Across SARS-CoV-2 Variants" by Seth Inzaule World Health Organization, Geneva, Switzerland

Oral Abstract: Using Data to Inform Interventions: Epidemiology of HIV, STIs, Mpox, and COVID-19

"QUESTIONS AND ANSWERS (Part 2)" by

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"INTRODUCTIONS" by

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study" by Amy Colson Community Resource Initiative

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"HepB-CpG Vaccine Is Superior to HepB-alum in People With HIV and Prior Vaccine Nonresponse: A5379" by Kristen Marks Weill Cornell Medicine, New York, NY, USA

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Efficacy, Safety, and Immunogenicity of H56:IC31 Vaccine for Prevention of Recurrent TB" by Alvaro Borges Statens Serum Institut

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Efficacy, Safety, and PK of BIC/FTC/TAF in Adults With HIV and Tuberculosis on Rifampicin at Week 24" by Anushka Naidoo Center for the AIDS Programme of Research in South Africa

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"Long-Acting Injectable CAB/RPV is Superior to Oral ART in PWH With Adherence Challenges: ACTG A5359" by Aadia I. Rana University of Alabama at Birmingham, Birmingham, AL, USA

Oral Abstract: Special Session: Clinical Late-Breaking Oral Abstracts

"QUESTIONS AND ANSWERS" by